TR200002737T2 - Aşı kompozisyonu - Google Patents

Aşı kompozisyonu

Info

Publication number
TR200002737T2
TR200002737T2 TR2000/02737T TR200002737T TR200002737T2 TR 200002737 T2 TR200002737 T2 TR 200002737T2 TR 2000/02737 T TR2000/02737 T TR 2000/02737T TR 200002737 T TR200002737 T TR 200002737T TR 200002737 T2 TR200002737 T2 TR 200002737T2
Authority
TR
Turkey
Prior art keywords
hib
prepared
vaccine composition
combination
antigene
Prior art date
Application number
TR2000/02737T
Other languages
English (en)
Inventor
Artois Claude
De Heyder Koen
Desmons Dr.P�Erre
Garcon Nathal�E
Mainil Roland
Original Assignee
Smithkline Beecham Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biologicals S.A. filed Critical Smithkline Beecham Biologicals S.A.
Publication of TR200002737T2 publication Critical patent/TR200002737T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Bu bulus,gerek hazirliksiz yapilmis gerekse sivi Hib/DTPa kombinasyon asilarinin, Hib müdahalesinden kaçinirken her bir antijenin,bunun en imünojenik oldugu alüminyum bazli kolaylastirici üzerine maksimum, kararli çekilmesini muhafaza etmek için hazirlanabildigi genel bir metotla ilgilidir. Bunu yaparken mevcut bulusa ait asilarla kombinasyon halindeki bogmaca antijenleri, en potansiyel formunda kararli bir sekilde tutulur.
TR2000/02737T 1998-03-25 1999-03-22 Aşı kompozisyonu TR200002737T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9806456.1A GB9806456D0 (en) 1998-03-25 1998-03-25 Vaccine composition

Publications (1)

Publication Number Publication Date
TR200002737T2 true TR200002737T2 (tr) 2000-12-21

Family

ID=10829286

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/02737T TR200002737T2 (tr) 1998-03-25 1999-03-22 Aşı kompozisyonu

Country Status (23)

Country Link
EP (1) EP1066053B8 (tr)
JP (1) JP2002507581A (tr)
KR (1) KR20010034630A (tr)
CN (1) CN1295481A (tr)
AR (1) AR014762A1 (tr)
AT (1) ATE335509T1 (tr)
AU (1) AU735619B2 (tr)
BR (1) BR9909037A (tr)
CA (1) CA2325436A1 (tr)
CO (1) CO4820442A1 (tr)
CZ (1) CZ20003536A3 (tr)
DE (1) DE69932709T2 (tr)
ES (1) ES2270590T3 (tr)
GB (1) GB9806456D0 (tr)
HU (1) HUP0101323A1 (tr)
IL (1) IL137999A0 (tr)
MY (1) MY133780A (tr)
NO (1) NO20004758L (tr)
NZ (1) NZ506604A (tr)
PL (1) PL343065A1 (tr)
TR (1) TR200002737T2 (tr)
WO (1) WO1999048525A1 (tr)
ZA (1) ZA200004956B (tr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020054884A1 (en) 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
AU750587B2 (en) * 1998-10-16 2002-07-25 Smithkline Beecham Biologicals (Sa) Adjuvant systems and vaccines
EP1004314A1 (fr) * 1998-11-26 2000-05-31 Pasteur Merieux MSD Vaccin T.d. Polio rappel pour une population vaccinée ou sensibilisée
SK288007B6 (sk) * 2000-06-29 2012-10-02 Glaxosmithkline Biologicals S. A. Multivalent vaccine composition, process for its producing, and its use
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
KR100385711B1 (ko) * 2000-07-05 2003-05-27 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
KR100401423B1 (ko) * 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
RU2323002C2 (ru) * 2001-07-26 2008-04-27 Чирон Срл. Вакцины, содержащие алюминиевые адъюванты и гистидин
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
FR2828406B1 (fr) 2001-08-08 2005-06-24 Aventis Pasteur Composition vaccinale bivalente havi
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0223355D0 (en) * 2002-10-08 2002-11-13 Chiron Spa Vaccine
ES2280809T3 (es) 2002-11-01 2007-09-16 Glaxosmithkline Biologicals S.A. Composicion inmunogenica.
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
CA2530434A1 (en) * 2003-06-23 2005-01-06 Aventis Pasteur, Inc. Immunization method against neisseria meningitidis serogroups a and c
US7867715B2 (en) 2003-08-05 2011-01-11 Alk-Abello A/S Method of evaluating the immunological activity of a vaccine
MXPA06008496A (es) 2004-02-02 2007-01-30 Ambrx Inc Polipeptidos de interferon humano modificados y sus usos.
US9931397B2 (en) 2005-06-27 2018-04-03 Glaxosmithkline Biologicals S.A. Immunogenic composition
EP1862176A1 (de) * 2006-05-31 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Ein Verfahren zur Herstellung einer Impfzusammensetzung
EP1862177A1 (de) * 2006-06-01 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Ein Verfahren zur Herstellung einer Impfzusammensetzung
PT2097102E (pt) * 2006-09-07 2012-08-03 Glaxosmithkline Biolog Sa Vacina de combinação tendo quantidades reduzidas de antigénio de poliovírus
GB0617602D0 (en) * 2006-09-07 2006-10-18 Glaxosmithkline Biolog Sa Vaccine
PE20100366A1 (es) 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
HRP20210242T4 (hr) 2010-08-23 2024-05-10 Wyeth Llc Stabilne formulacije antigena iz bakterije neisseria meningitidis rlp2086
CN103096920B (zh) 2010-09-10 2016-03-23 惠氏有限责任公司 脑膜炎奈瑟球菌orf2086抗原的非脂质化变体
CN102198270B (zh) * 2011-05-16 2012-06-27 大连汉信生物制药有限公司 一种含铝佐剂乙肝疫苗的制备方法
EP2822584A1 (en) * 2012-03-08 2015-01-14 Novartis AG Combination vaccines with tlr4 agonists
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
BR122016004924A2 (pt) 2012-03-09 2019-07-30 Pfizer Inc. Polipeptídeo isolado e composições imunogênicas compreendendo os mesmos
MX362793B (es) 2013-03-08 2019-02-13 Janssen Vaccines & Prevention Bv Vacuna acelular contra pertussis.
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN106075428A (zh) * 2015-07-01 2016-11-09 北京科兴中维生物技术有限公司 一种免疫原性组合物及其制备方法
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3655024A1 (en) 2017-07-18 2020-05-27 Serum Institute of India Private Limited An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof
EP3749354A4 (en) * 2018-02-05 2021-11-03 Diamyd Medical AB NEW COMPOSITION AND ITS USE
JOP20190242A1 (ar) 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69319728T2 (de) * 1992-05-23 1999-02-04 Smithkline Beecham Biolog Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
PL184872B1 (pl) * 1995-06-23 2003-01-31 Smithkline Beecham Biolog Kombinowana szczepionkaĆ zestaw do przygotowania kombinowanej szczepionkiĆ sposób wytwarzania kombinowanej szczepionki i jej zastosowanie
GB9611501D0 (en) * 1996-06-03 1996-08-07 Smithkline Beecham Biolog Vaccine compositions

Also Published As

Publication number Publication date
MY133780A (en) 2007-11-30
PL343065A1 (en) 2001-07-30
CN1295481A (zh) 2001-05-16
ATE335509T1 (de) 2006-09-15
AU3417299A (en) 1999-10-18
WO1999048525A8 (en) 1999-11-11
WO1999048525A1 (en) 1999-09-30
EP1066053B1 (en) 2006-08-09
EP1066053B8 (en) 2006-12-13
DE69932709D1 (de) 2006-09-21
KR20010034630A (ko) 2001-04-25
AR014762A1 (es) 2001-03-28
ZA200004956B (en) 2002-02-27
GB9806456D0 (en) 1998-05-27
ES2270590T3 (es) 2007-04-01
NO20004758L (no) 2000-11-08
CO4820442A1 (es) 1999-07-28
NO20004758D0 (no) 2000-09-22
NZ506604A (en) 2003-02-28
DE69932709T2 (de) 2007-08-16
BR9909037A (pt) 2000-12-05
IL137999A0 (en) 2001-10-31
CA2325436A1 (en) 1999-09-30
EP1066053A1 (en) 2001-01-10
AU735619B2 (en) 2001-07-12
JP2002507581A (ja) 2002-03-12
HUP0101323A1 (hu) 2001-08-28
CZ20003536A3 (cs) 2001-08-15

Similar Documents

Publication Publication Date Title
TR200002737T2 (tr) Aşı kompozisyonu
ATE295895T1 (de) Genetischer impfstoff gegen den immunschwäche virus
JP2012001548A (ja) 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
CY1107457T1 (el) Εμβoλιο κατa του hpv
BR0000126A (pt) Adjuvantes para uso em vacinas
DE69936780D1 (de) Antikörper gegen eine lar-phosphatase untereinheit
ATE501726T1 (de) Zusammensetzung mit immunogenen mikroteilchen
BR9708387A (pt) Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
BRPI0407352A (pt) Composição para o cuidado oral, e, métodos para efetuar a estabilidade aumentada em uma composição oral contendo enzimas, e para a preparação de uma composição para o cuidado oral aquosa
DE58904760D1 (de) Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen.
AR003006A1 (es) Composición de vacuna combinada que comprende un polisacarido capsular de haemophilus influenzae b conjugado con una proteina portadora adsorbido sobre fosfato de aluminio y uno u otros antígenos distintos, métodos para producirla, y su uso para preparar un medicamento
TR200001543T2 (tr) Dengelenmiş saç bakım ürünleri
DE602004028468D1 (de) Haltung von immunantworten gegen mhc-klasse-i-beschränkte epitope, für prophylaktische oder therapeutische zwecke
Handler Dependency and discretion.
AR039429A1 (es) Metodo para aumentar la eliminacion especifica mediada por la respuesta inmune endogena de la poblacion de celulas patogenicas en un animal huesped inmunizado previamente, composicion y combinacion que comprenden un auxiliar th1 y un conjugado hapten-portador de utilidad en el mismo.
BR112022014830A2 (pt) Formulações de vacina para coronavírus
BR9806248A (pt) Composição cosmética e/ou dermatológica, composição pronta para uso, processo para tintura de fibras queratìnicas, dispositivo ou kit de tintura de multi-compartimentos e processo para tratamento de fibras queratìnicas.
UY24654A1 (es) Composición de vacuna contra la malaria
ES2177927T3 (es) Composicion para provocar una reaccion inmunologica a un determinante antigenico no proteinico.
Ada Prospects for a vaccine against HIV
BR9707785A (pt) Parapoxvírus que contém dna estrangeiro preparação dos mesmos e uso dos mesmos em vacinas
BR0012433A (pt) Vìrus recombinante, infeccioso de doença bursal infecciosa, método para obter o mesmo, ibdv mosaico infeccioso (mibdv), e, vacina
DE3889581D1 (de) Monoklonale Antikörper gegen spezifische antigene Regionen des humanen Immundefizienzvirus und Methoden zur Verwendung.
HUP9801917A2 (hu) Immunogén készítmény, eljárás annak előállítására és vakcinaként történő alkalmazására
AR026833A1 (es) Tinturas curables con energia y metodos para su preparacion.